{2-[(叔-丁氧基羰基)氨基]-2-甲基丙氧基}乙酸 | 193085-32-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: {2-[(叔-丁氧基羰基)氨基]-2-甲基丙氧基}乙酸
• 英文名称: (2-tert-butoxycarbonylamino-2-methylpropoxy)acetic acid
• 英文别名: 2-[2-(tert-butoxycarbonylamino)-2-methylpropoxy]acetic acid；(2-tert-butoxycarbonylamino-2-methyl-propoxy)-acetic acid；(2-tert-butoxycarbonylamino-2-methyl-propoxy)acetic acid；(2-tert Butoxycarbonylamino-2-methylpropoxy)acetic acid；(2-t-Butoxycarbonylamino-2-methylpropoxy)acetic acid；(2-Bocamino-2-methyl-propoxy)-acetic acid；2-[2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]acetic acid
• CAS: 193085-32-4
• 化学式: C₁₁H₂₁NO₅
• 分子量: 247.291
• InChiKey: MDTMSMLZHVQGPA-UHFFFAOYSA-N

物化性质

• 沸点：
  399.9±22.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  二甲羟胺盐酸盐 、 {2-[(叔-丁氧基羰基)氨基]-2-甲基丙氧基}乙酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以96%的产率得到[2-(tert-butoxycarbonylamino)-2-methylpropyl]-N-methoxy-N-methylcarbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS
  [FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS

  摘要：

  这项发明提供了替代的N-杂环羧酰胺和相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗疾病（例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病）的方法。

  公开号：

  WO2021055627A1
• 作为产物：
  描述：

  (2-tert-butoxycarbonylamino-2-methyl-propoxy)-acetic acid ethyl ester 在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 {2-[(叔-丁氧基羰基)氨基]-2-甲基丙氧基}乙酸
  参考文献：
  名称：

  Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals

  摘要：

  The structural requirements for N-terminal features for the minimal structure of growth hormone secretagogues derived from ipamorelin are investigated. It is found, that incorporation of nonpolar peptidomimetic amino acids at the N-terminal can replace the Aib-His moiety and lead to compounds with high in vitro potency with respect to their growth hormone secretagogue properties. New unnatural amino acids with double bonds, ether-linkages, and 1,3-phenylene-moieties in the backbone proved to be valuable dipeptidomimetics. Using them, growth hormone secretagogues with high potencies were obtained. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80086-5

文献信息

• Compounds with growth hormone releasing properties
  申请人：Novo Nordisk A/S

  公开号：US05977178A1

  公开（公告）日：1999-11-02

  Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

  具有一般式I的肽类模拟化合物##STR1##，其中a和b独立地为1或2，R.sup.1和R.sup.2独立地为H或C.sub.1-6烷基，G和J独立地为芳香族等，D和E独立地为几种不同的基团，具有改善生物利用度的生长激素分泌素。
• [EN] N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS<br/>[FR] COMPOSES DE N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE EN TANT QU'INHIBITEURS DE RECAPTAGE DE LA TACHYKININE ET/OU DE LA SEROTONINE
  申请人：GLAXO GROUP LTD

  公开号：WO2004005255A1

  公开（公告）日：2004-01-15

  The present invention relates to heterocyclic derivatives of formula (1) wherein R1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R1 represents a 4,5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4,5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH2)pR6, wherein p is zero or an integer from 1 to 4 and wherein R and R2- R6 are each as defined in the description and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  本发明涉及式（1）的杂环衍生物，其中R1代表一个5或6成员杂芳基团，在其中5成员杂芳基团至少含有氧、硫或氮中选择的一个杂原子，而6成员杂芳基团含有1至3个氮原子，或者R1代表一个4、5或6成员杂环基团，其中所述的5或6成员杂芳基或4、5或6成员杂环基团可以选择地被1至3个取代基取代，所述取代基可以相同或不同，选择自(CH2)pR6，其中p为零或1至4的整数，其中R和R2-R6如描述中定义，并且其药学上可接受的盐和溶剂化合物；其制备方法及其在通过催产素介导的疾病和/或通过选择性抑制血清素再摄取转运蛋白的治疗中的用途。
• [EN] COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES<br/>[FR] COMPOSES AVEC DES PROPRIETES DE LIBERATION DE L'HORMONE DE CROISSANCE
  申请人：NOVO NORDISK A/S

  公开号：WO1997023508A1

  公开（公告）日：1997-07-03

  (EN) Compounds of peptide mimetic nature having general formula (I), wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups, are growth hormone secretagogous with improved bioavailability.(FR) L'invention concerne un peptide de nature mimétique ayant la formule générale (I). Dans cette formule, a et b sont, d'une manière indépendante 1 ou 2, R1 et R2 sont, d'une manière indépendante H ou C1-6 alkyle, G et J sont, d'une manière indépendante, entre autres, des groupes aromatiques et D et E sont, d'une manière indépendante, plusieurs groupes différents. Ces peptides favorisent la sécrétion de l'hormone de croissance et améliorent sa biodisponibilité.

  化合物具有类肽类似物性质的通式(I)，其中a和b独立地为1或2，R1和R2独立地为H或C1-6烷基，G和J独立地为芳香族等基团，D和E独立地为多种不同基团，具有改善生物利用度的生长激素分泌剂。
• Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels
  申请人：Bridges Alexander

  公开号：US20050143349A1

  公开（公告）日：2005-06-30

  The invention provides phosphorus containing compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to a subject, wherein the phosphorus containing compounds are of the Formula I: wherein B 1 , B 2 , B 3 , B 4 , Ar, F, E, G, Y 1 , Y 2 , Y 3 , X, U, V, R 4 , R 5 , Q, D, n, Het, Z 1 , and Z 2 , are as defined herein.

  本发明提供了含磷化合物、包含该化合物的药物组合物以及向受试者施用该化合物的方法，其中含磷化合物为式 I： 其中 B 1 , B 2 , B 3 , B 4 , Ar, F, E, G, Y 1 , Y 2 , Y 3 , X, U, V, R 4 , R 5 , Q, D, n, Het, Z 1 和 Z 2 如本文所定义。
• Demonstration of the strength of focused combinatorial libraries in SAR optimisation of growth hormone secretagogues
  作者：M Ankersen

  DOI：10.1016/s0223-5234(99)00214-7

  日期：1999.10

  A series of 96 growth hormone secretagogues, derived from ipamorelin are described. The compounds are prepared as a 6 x 4 x 4 member library on solid support using a PAL resin. The compounds are all acylated dipeptides, based on two aromatic amino acids and a free amino N-terminal. All compounds are characterised by HPLC, LC-MS and their ability to release GH in a pituitary cell based assay. The most potent compounds show EC50 values at 1 nM and are full agonists. We demonstrate the strength of focused combinatorial libraries and confirm the pitfall in broad SAR exploration by giving examples where selected fragments obviously show poor receptor interaction except in very defined structural arrangements. (C) 1999 Editions scientifiques et medicales Elsevier SAS.